Most Read Articles
Dr. Joseph Delano Fule Robles, 4 days ago

A recent study conducted by The University of Hong Kong (HKU) revealed that long-term use of proton pump inhibitors (PPIs) is associated with a significantly increased risk of gastric cancer even in patients who have had Helicobacter pylori eradicated. 

01 Aug 2017
New drug applications approved by US FDA as of 1 - 15 June 2017 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
27 May 2016
TRIPLIXAM – Perindopril arginine, Indapamide, Amlodipine FC tab – Servier
01 Jul 2016
Get access to disease management charts, dosage guidelines and much more.

ENABLEX Now Approved in Malaysia

22 May 2015
Reclassification of MIMS Class – ENABLEX
In MIMS 140th edition (1st Issue 2015), there was an error classifying Enablex under 10f. Other Drugs Acting on the Genito-Urinary System. With effect from MIMS 141st edition (2nd Issue 2015), Enablex will be reclassified under 10e. Drugs for Bladder & Prostate Disorder to reflect a more accurate classification based on its therapeutic use.


ENABLEX – Darifenacin Hydrobromide 7.5mg Prolonged Release Tablet
 A highly selective M3 antagonist developed for treating overactive bladder (OAB) 1, 2
• Improves Incontinence Episodes (IEs) per week, Urgency Episodes (UEs) per day and micturitions per day in OAB patients with 5-50 episodes of incontinence per week 3
• No significant effect on heart rate 4
• Does not prolong the QT/QTc interval 5
• Does not impair memory or other cognitive functions 6
 
References:
1. KAY G, WESNES K. 2005. Pharmacodynamic effects if darifenacin, a muscarinic M3 selective receptor antagonist for the treatment of overactive bladder, in healthy volunteers. BJU International; 96:1055-62.
2. ENABLEX® Package Insert.
3. CHAPPLE C, STEERS W, NORTON P, MILLARD R, KRALIDIS G, GLAVIND K, et al. 2005. A pooled analysis of three phase III studies to investigate the efficacy, tolerability and safety of darifenacin, a muscarinic M3 selective receptor antagonist, in the treatment of overactive bladder. BJU International; 95:993-1001.
4. OLSHANSKY B, EBINGER U, BRUM J, EGERMARK M, VIEGAS A, REKEDA L. 2008. Differential Pharmacological Effects of Antimuscarinic Drugs on Heart Rate: Double-blind, Crossover Study With Tolterodine and Darifenacin in Healthy Participants ≥50 Years. J Cardiovasc Pharmacol Ther; doi:10.1177/1074248408325404.
5. SERRA D, AFFRIME M, BEDIGIAN M, GREIG G, MILOSAVLJEV S, SKERJANEC A, et al. 2005. QT and QTc Interval With Standard and Supratherapeutic Doses of Darifenacin, a Muscarinic M3 Selective Receptor Antagonist for the Treatment of Overactive Bladder. J Clin Pharmacol ; 45:1038-1047
6. KAY G, EBINGER U. 2008. Preserving cognitive function for patients with overactive bladder: evidence for a differential effect with darifenacin. Int J Clin Pract; 62(11):1792-1800.

Related MIMS Drugs

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacy - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
Dr. Joseph Delano Fule Robles, 4 days ago

A recent study conducted by The University of Hong Kong (HKU) revealed that long-term use of proton pump inhibitors (PPIs) is associated with a significantly increased risk of gastric cancer even in patients who have had Helicobacter pylori eradicated. 

01 Aug 2017
New drug applications approved by US FDA as of 1 - 15 June 2017 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
27 May 2016
TRIPLIXAM – Perindopril arginine, Indapamide, Amlodipine FC tab – Servier
01 Jul 2016
Get access to disease management charts, dosage guidelines and much more.